Intelsat Selected by Air Canada for Expanded Fleet Connectivity
5.9.2023 18:00:00 EEST | Business Wire | Press release
Air Canada and Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of in-flight connectivity (IFC), today announced an agreement for Intelsat to provide connectivity systems for nearly 100 additional aircraft across the airline’s fleet, including Intelsat’s new multi-orbit electronically steered array (ESA) antenna for aircraft in the airline’s regional jet fleet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905161445/en/
Intelsat currently operates in-flight internet on 240 aircraft spanning Air Canada, Rouge and Air Canada Express. The new program includes IFC installations on three types of Air Canada aircraft. (Photo: Business Wire)
“Intelsat has been delivering reliable in-flight connectivity to Air Canada and its passengers for 14 years,” said Dave Bijur, Senior Vice President Commercial for Intelsat Commercial Aviation. “Air Canada’s leadership will continue for decades to come thanks to this investment in 2Ku connectivity for the 737 MAX fleet and the decision to install Intelsat’s innovative multi-orbit service across their regional jet operation.”
“The efforts and the commitment of Intelsat’s team and their service partners made the difference for us. We’re confident Intelsat provides proven technology, an extensible platform and network, and the right vision for the future of in-flight connectivity,” said Mark Nasr, Air Canada’s Executive Vice President, Marketing and Digital, and President of Aeroplan. “Through our Bell partnership, equipment installation schedule, and strong conviction around the importance of in-flight connectivity, we seek to offer our customers the best and most consistently available offering in the industry.”
Intelsat currently operates in-flight internet on 240 aircraft spanning Air Canada, Rouge and Air Canada Express. The new program includes IFC installations on three types of Air Canada aircraft:
- Boeing 737 MAX aircraft – the fleet of 40 aircraft will be equipped starting this year with Intelsat’s 2Ku IFC system.
- Embraer 175 and Mitsubishi CRJ-900 aircraft (currently installed with Intelsat’s air-to-ground system) – The 55 aircraft are currently flown by Air Canada’s Jazz regional partner and will be upgraded with Intelsat’s new ESA antenna starting in 2024.
Air Canada’s flag carrier and its regional partner Jazz together operate over 300 aircraft and they offer more Wi-Fi equipped flights than any other airline in Canada. The relationship with Intelsat will serve as a key enabler as Air Canada seeks to offer its customers the fastest and most consistently available Internet connectivity in the industry, throughout its global network.
Intelsat’s 2Ku solution is the industry’s leader due to its combination of a low-profile, fuselage-mounted antenna and its reliable on-wing performance. The smaller aircraft in the airline’s regional jet fleet will benefit from Intelsat’s new ESA which is less than three inches tall and interoperates on both Intelsat’s family of geo-stationary satellites and on OneWeb’s constellation of Low Earth Orbit (LEO) satellites. This strategy enables Air Canada to deliver the highest quality inflight internet experience available to airlines, wherever it flies.
About Intelsat
Intelsat’s worldwide team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation global network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
About Air Canada
Air Canada is Canada's largest airline, the country’s flag carrier and a founding member of Star Alliance, the world's most comprehensive air transportation network. Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and Internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, where members can earn or redeem points on the world’s largest airline partner network of 45 airlines, plus through an extensive range of merchandise, hotel and car rental rewards. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada aims to achieve an ambitious net zero emissions goal from all global operations by 2050. Air Canada shares are publicly traded on the TSX in Canada and the OCTQX in the U.S.
Follow Us on Social Media:
Twitter, LinkedIn, Facebook, Instagram, YouTube
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905161445/en/
Contact information
Media Contact:
Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
